Skip to content Skip to footer

Description

  • Febuxostat, a potent non-purine selective Xanthine Oxidase( XO) inhibitor, inhibits both oxidized and reduced types of XO unlike allopurinol. As a result of its selectivity and structural differences, febuxostat tends to cause fewer adverse events when compared with allopurinol
  • With advantage of a fixed daily dose 120mg
  • No dose adjustment is necessary in patients with mild or moderate renal impairment
  • No hypersensitivity profile unlike allopurinol
  • Reduces higher rates of treatment-related complications and costs